Virtu Financial LLC bought a new stake in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) during the 4th quarter, HoldingsChannel.com reports. The firm bought 5,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $314,000.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Municipal Employees Retirement System of Michigan lifted its position in shares of Eagle Pharmaceuticals by 68.1% in the third quarter. Municipal Employees Retirement System of Michigan now owns 3,210 shares of the specialty pharmaceutical company’s stock valued at $191,000 after acquiring an additional 1,300 shares in the last quarter. Campbell Newman Asset Management Inc. purchased a new position in shares of Eagle Pharmaceuticals in the fourth quarter valued at approximately $200,000. Schroder Investment Management Group purchased a new position in shares of Eagle Pharmaceuticals in the third quarter valued at approximately $219,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Eagle Pharmaceuticals in the third quarter valued at approximately $257,000. Finally, SG Americas Securities LLC lifted its position in shares of Eagle Pharmaceuticals by 60.8% in the third quarter. SG Americas Securities LLC now owns 4,511 shares of the specialty pharmaceutical company’s stock valued at $269,000 after acquiring an additional 1,706 shares in the last quarter.
In related news, Director Sander A. Flaum sold 2,340 shares of the stock in a transaction that occurred on Tuesday, March 6th. The stock was sold at an average price of $53.94, for a total value of $126,219.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 19.50% of the stock is currently owned by company insiders.
Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its quarterly earnings results on Monday, February 26th. The specialty pharmaceutical company reported $0.84 EPS for the quarter, missing the consensus estimate of $1.00 by ($0.16). Eagle Pharmaceuticals had a net margin of 21.94% and a return on equity of 34.16%. The company had revenue of $46.80 million during the quarter, compared to analyst estimates of $53.65 million. During the same period in the prior year, the business posted $3.52 EPS. Eagle Pharmaceuticals’s revenue for the quarter was down 42.3% compared to the same quarter last year. research analysts forecast that Eagle Pharmaceuticals Inc will post 2.57 EPS for the current year.
EGRX has been the topic of several research reports. BidaskClub upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, December 2nd. ValuEngine downgraded Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Zacks Investment Research downgraded Eagle Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Piper Jaffray Companies restated a “buy” rating and issued a $79.00 target price on shares of Eagle Pharmaceuticals in a research report on Tuesday, January 30th. Finally, Mizuho reaffirmed a “sell” rating and issued a $37.00 price target on shares of Eagle Pharmaceuticals in a report on Monday, February 26th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $62.33.
TRADEMARK VIOLATION WARNING: “5,870 Shares in Eagle Pharmaceuticals Inc (EGRX) Acquired by Virtu Financial LLC” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3261121/5870-shares-in-eagle-pharmaceuticals-inc-egrx-acquired-by-virtu-financial-llc.html.
Eagle Pharmaceuticals Profile
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.
Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals Inc (NASDAQ:EGRX).
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.